The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

In the oncology world, there’s been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years.

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Oncolytics Biotech (ONCY – Research Report). The ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

Taken together, the BRACELET-1 results provide compelling support for the potential of pelareorep-based combination therapy ...

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...